- The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology
- Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization
- The company has 20 patents granted and over 50 pending patents in over 40 countries around the world
- The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated that administration of colchicine using the company’s proprietary DehydraTECH(TM), formulation and processing, resulted in increased delivery, according to a company press release (https://ibn.fm/AXBcz).
Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines.
The study was performed using Sprague-Dawley rats, with 20 dosed through oral gavage using DehydraTECH or control colchicine formulations. Performed by an independent, premier animal testing laboratory in the United States, the study evaluated both peak concentration and total drug delivery into the rodent’s bloodstream. As colchicine has a narrow therapeutic index, which means there is a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH it can improve its bioavailability beyond current levels of approximately 45 percent, which would potentially allow lower dosing requirements.
Lexaria’s DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro, and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. This research has initiated new patent applications and opened the possibilities for improved drug delivery.
The company has licensed its proprietary technology to multiple companies for use in different industries, including tobacco and nicotine products, cannabinoid beverages and edibles and more. Lexaria’s intellectual property portfolio consists of 20 patents granted and more than 50 patents pending in over 40 countries worldwide.
Lexaria is currently collaborating with the National Research Council (“NRC”), the Canadian government’s leading research and technology organization. The Company has already filed for patent protection for specific nicotine delivery, NSAIDs, vitamins, estrogen, testosterone, terpenes, cannabinoids, PDE5 inhibitors (like Viagra), tobacco, and more.
DehydraTECH is designed for formulating and delivering fat-soluble drugs and active ingredients, increasing their effectiveness and improving the way active pharmaceutical ingredients enter the bloodstream. The benefits of a DehydraTECH-enabled drug or consumer product are:
- Delivery is sped up, making the effects felt by the consumer in a matter of minutes
- The bioavailability is increased, making the delivery to the bloodstream much more effective and possibly requiring lower doses
- Animal testing has evidenced that there is a significant increase in the amount of the formulation crossing the blood barrier
- For consumer products, eliminates or reduces the need for sweeteners that are often used to mask the unwanted taste of the substance
This technology has the potential to revolutionize the global market for advanced drug delivery systems by changing the way treatments are administered and increasing overall bioabsorption and bioavailability. The drug delivery market is expected to reach a revenue of $310 billion by 2025 from $231 billion in 2020, marking a CAGR of 6.1% (https://ibn.fm/gGqYu). Right now, one of three areas of focus for Lexaria is on the antiviral drug market, which is anticipated to reach $52.1 billion in 2021 and grow to $66.7 billion by 2025.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
